Medical analytics platform developer Aetion raised $36.4m in an Amgen Ventures-backed round that took its total funding to $50m.
Aetion, the US-based creator of an analytics platform for drug developers, received $36.4m in funding yesterday from investors including Amgen Ventures, the corporate venturing vehicle for pharmaceutical company Amgen.
The series B round was led by venture capital firm New Enterprise Associates (NEA) and also featured healthcare investment firm Oxeon Ventures and VC firms Flare Capital Partners and Lakestar.
Aetion’s Evidence Platform combines data sourced from places such as health insurance claims, electronic health records, registries and clinical trials and…
